Compass Therapeutics/$CMPX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Compass Therapeutics
Compass Therapeutics Inc is a clinical-stage oncology-focused biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to target the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-A, Bispecific, and CTX-8371.
Ticker
$CMPX
Sector
Primary listing
Employees
39
Headquarters
Website
CMPX Metrics
BasicAdvanced
$981M
-
-$0.42
1.29
-
Price and volume
Market cap
$981M
Beta
1.29
52-week high
$6.88
52-week low
$1.33
Average daily volume
2M
Financial strength
Current ratio
15.021
Quick ratio
14.956
Long term debt to equity
4.486
Total debt to equity
4.995
Profitability
EBITDA (TTM)
-72.563
Management effectiveness
Return on assets (TTM)
-25.29%
Return on equity (TTM)
-41.29%
Valuation
Price to book
4.94
Price to tangible book (TTM)
4.94
Price to free cash flow (TTM)
-17.48
Free cash flow yield (TTM)
-5.72%
Free cash flow per share (TTM)
-0.312
Growth
Earnings per share change (TTM)
17.32%
3-year earnings per share growth (CAGR)
4.18%
What the Analysts think about CMPX
Analyst ratings (Buy, Hold, Sell) for Compass Therapeutics stock.
CMPX Financial Performance
Revenues and expenses
CMPX Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Compass Therapeutics stock?
Compass Therapeutics (CMPX) has a market cap of $981M as of March 18, 2026.
What is the P/E ratio for Compass Therapeutics stock?
The price to earnings (P/E) ratio for Compass Therapeutics (CMPX) stock is 0 as of March 18, 2026.
Does Compass Therapeutics stock pay dividends?
No, Compass Therapeutics (CMPX) stock does not pay dividends to its shareholders as of March 18, 2026.
When is the next Compass Therapeutics dividend payment date?
Compass Therapeutics (CMPX) stock does not pay dividends to its shareholders.
What is the beta indicator for Compass Therapeutics?
Compass Therapeutics (CMPX) has a beta rating of 1.29. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.